Anavex Agreement with the Roskamp Institute to Advance the Clinical Development of ANAVEX PLUS

New York, NY — January 13, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that they have established an agreement with The Roskamp Institute for the clinical development of ANAVEX PLUS, a new combination drug of ANAVEX 2-73 and donepezil (Aricept®) for the treatment of Alzheimer’s disease.  This study…